Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

Inclusion Criteria: * Not currently pregnant or lactating and is highly unlikely to conceive * Body Mass Index (BMI) between 20-30 kilograms per meter squared (kg/m2) inclusive. * Body weight, as reported by patient, stable (±2 kg) for \>6 weeks * Plasma low density lipoprotein cholesterol (LDL-C) between 130 and 180 milligrams per deciliter (mg/dL) inclusive. Note: One retest allowed. * Triglyceride (TG) concentrations ≤150 mg/dL. Note: One retest allowed. * Fasting blood glucose \<110 mg/dL and hemoglobin A1c (HbA1C) ≤ 6 percent at Visit 1. Note: One retest allowed. * Liver transaminases (ALT, AST) ≤1.5 x upper limit of normal (ULN) and no active liver disease. Note: One retest allowed. * Creatine Phosphokinase (CPK) ≤2x ULN. Note: One retest allowed. * Willingness to maintain a stable diet for the duration of the study. * Can understand and comply with study procedures and signs a written informed consent. * Patient is ≥80 precent compliant with dosing during Placebo Run-In Period or, in the opinion of the investigator, is able to maintain ≥80 percent therapy compliance during the active treatment period of the study. Exclusion Criteria: * Lipid-lowering therapy and replacement of this therapy with study medication is considered inappropriate by the investigator. * Consumes an average of more than 2 alcoholic drinks per day. * Smokes. * Currently engages in a vigorous exercise regimen or intensive exercise bouts \>4x per month. * Treated with any other investigational drug within 30 days of Visit 1. * Hypersensitivity or intolerance to ezetimibe or any component of this medication. * Any condition or situation which poses a risk to the patient or interfere with participation in the study. * Congestive heart failure. * Uncontrolled cardiac arrhythmias. * History of myocardial infarction, stroke, or any other clinical manifestation of coronary, cerebral, or peripheral vascular disease. * Uncontrolled hypertension * Impaired renal function, nephrotic syndrome or other clinically significant renal disease at Visit 1. * Active or chronic hepatobiliary or hepatic disease. * History of irritable bowel syndrome, ileal bypass, gastric bypass or any gastrointestinal disorder/condition associated with malabsorption. * Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins. * Type I or Type II diabetes mellitus. * Disorders of the hematologic, digestive, or central nervous systems including cerebrovascular disease and degenerative disease that would limit study evaluation or participation. * Human Immunodeficiency Virus (HIV) positive. * History of cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas). * History of uncontrolled psychiatric illness or drug/alcohol abuse within the past 5 years. Individuals with psychiatric illness adequately controlled and stable on pharmacotherapy may be enrolled at the discretion of the investigator. * Lipid-lowering agents taken within 6 weeks and fibrates taken within 8 weeks prior to visit 3. * Cardiovascular medications are acceptable provided the patient has been on a stable regimen for at least 6 weeks prior to Visit 3 and indicates a willingness to continue the stable regimen for the duration of the study. * Supplementation with antioxidants beyond a standard multivitamin for the duration of the study. * Psyllium, other fiber-based laxatives, and/or over the counter (OTC) therapies known to affect serum lipid levels taken within 6 weeks of Visit 3. * Female patients receiving hormone replacement therapy, any estrogen antagonist/agonist or hormonal contraceptives. * Treatment with cyclosporine except for ophthalmic indication * Anti-obesity medications such as orlistat or sibutramine taken within 3 months prior to Visit 1. * Therapeutic doses of systemic corticosteroids except inhaled steroid therapy (for example, Pulmicort®) maintained on a stable dosing regimen for at least 6 weeks prior to randomization (Visit 3) and throughout the duration of the study